Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
SGRY vs AMSF vs KNTK vs USPH vs SEM
Revenue, margins, valuation, and 5-year total return — side by side.
Insurance - Specialty
Oil & Gas Midstream
Medical - Care Facilities
Medical - Care Facilities
SGRY vs AMSF vs KNTK vs USPH vs SEM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Insurance - Specialty | Oil & Gas Midstream | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $1.87B | $569M | $3.33B | $897M | $2.04B |
| Revenue (TTM) | $3.34B | $325M | $1.73B | $695M | $5.52B |
| Net Income (TTM) | $-76M | $46M | $228M | $11M | $134M |
| Gross Margin | 22.8% | 47.6% | 24.8% | 22.0% | 10.6% |
| Operating Margin | 11.8% | 17.8% | 8.2% | 12.2% | 5.8% |
| Forward P/E | 38.0x | 14.4x | 42.4x | 20.6x | 13.1x |
| Total Debt | $4.02B | $491K | $3.87B | $426M | $3.70B |
| Cash & Equiv. | $240M | $62M | $4M | $36M | $27M |
SGRY vs AMSF vs KNTK vs USPH vs SEM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Surgery Partners, I… (SGRY) | 100 | 106.8 | +6.8% |
| AMERISAFE, Inc. (AMSF) | 100 | 49.4 | -50.6% |
| Kinetik Holdings In… (KNTK) | 100 | 702.3 | +602.3% |
| U.S. Physical Thera… (USPH) | 100 | 79.6 | -20.4% |
| Select Medical Hold… (SEM) | 100 | 189.2 | +89.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SGRY vs AMSF vs KNTK vs USPH vs SEM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SGRY lags the leaders in this set but could rank higher in a more targeted comparison.
AMSF carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.23, Low D/E 0.2%, current ratio 0.32x
- Beta 0.23, yield 8.4%, current ratio 0.32x
- 14.3% margin vs SGRY's -2.3%
- Beta 0.23 vs SGRY's 1.04, lower leverage
KNTK is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- Dividend streak 3 yrs, beta 0.60, yield 16.5%
- Rev growth 19.0%, EPS growth 157.8%, 3Y rev CAGR 13.3%
- 19.0% revenue growth vs AMSF's 2.6%
- 16.5% yield, 3-year raise streak, vs USPH's 3.1%, (1 stock pays no dividend)
Among these 5 stocks, USPH doesn't own a clear edge in any measured category.
SEM ranks third and is worth considering specifically for long-term compounding.
- 158.5% 10Y total return vs AMSF's 31.8%
- Lower P/E (13.1x vs 20.6x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.0% revenue growth vs AMSF's 2.6% | |
| Value | Lower P/E (13.1x vs 20.6x) | |
| Quality / Margins | 14.3% margin vs SGRY's -2.3% | |
| Stability / Safety | Beta 0.23 vs SGRY's 1.04, lower leverage | |
| Dividends | 16.5% yield, 3-year raise streak, vs USPH's 3.1%, (1 stock pays no dividend) | |
| Momentum (1Y) | +28.0% vs SGRY's -38.2% | |
| Efficiency (ROA) | 5.6% ROA vs SGRY's -0.9%, ROIC 21.9% vs 4.1% |
SGRY vs AMSF vs KNTK vs USPH vs SEM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SGRY vs AMSF vs KNTK vs USPH vs SEM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AMSF leads in 2 of 6 categories
SEM leads 1 • KNTK leads 1 • SGRY leads 0 • USPH leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
AMSF leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SEM is the larger business by revenue, generating $5.5B annually — 17.0x AMSF's $325M. AMSF is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to SGRY's -2.3%. On growth, AMSF holds the edge at +10.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3.3B | $325M | $1.7B | $695M | $5.5B |
| EBITDAEarnings before interest/tax | $572M | $58M | $534M | $107M | $465M |
| Net IncomeAfter-tax profit | -$76M | $46M | $228M | $11M | $134M |
| Free Cash FlowCash after capex | $208M | $8M | $441M | $67M | $117M |
| Gross MarginGross profit ÷ Revenue | +22.8% | +47.6% | +24.8% | +22.0% | +10.6% |
| Operating MarginEBIT ÷ Revenue | +11.8% | +17.8% | +8.2% | +12.2% | +5.8% |
| Net MarginNet income ÷ Revenue | -2.3% | +14.3% | +13.2% | +1.5% | +2.4% |
| FCF MarginFCF ÷ Revenue | +6.2% | +2.5% | +25.5% | +9.6% | +2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.5% | +10.3% | -7.5% | +7.7% | +5.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +6.7% | -8.5% | -2.4% | -115.0% | -18.2% |
Valuation Metrics
SEM leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 12.3x trailing earnings, AMSF trades at a 70% valuation discount to USPH's 41.5x P/E. On an enterprise value basis, AMSF's 8.5x EV/EBITDA is more attractive than KNTK's 13.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.9B | $569M | $3.3B | $897M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $5.7B | $508M | $7.2B | $1.3B | $5.7B |
| Trailing P/EPrice ÷ TTM EPS | -23.46x | 12.27x | 18.43x | 41.55x | 13.93x |
| Forward P/EPrice ÷ next-FY EPS est. | 37.99x | 14.42x | 42.44x | 20.63x | 13.06x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 10.00x | 8.53x | 13.14x | 12.52x | 12.04x |
| Price / SalesMarket cap ÷ Revenue | 0.57x | 1.80x | 1.89x | 1.15x | 0.37x |
| Price / BookPrice ÷ Book value/share | 0.52x | 2.30x | 1.04x | 1.16x | 1.00x |
| Price / FCFMarket cap ÷ FCF | 9.57x | 63.83x | 44.78x | 14.71x | 5.33x |
Profitability & Efficiency
AMSF leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
KNTK delivers a 21.1% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-2 for SGRY. AMSF carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to SEM's 1.82x. On the Piotroski fundamental quality scale (0–9), AMSF scores 7/9 vs KNTK's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.2% | +9.7% | +21.1% | +1.4% | +6.6% |
| ROA (TTM)Return on assets | -0.9% | +5.6% | +4.2% | +0.9% | +2.3% |
| ROICReturn on invested capital | +4.1% | +21.9% | +1.9% | +5.6% | +4.8% |
| ROCEReturn on capital employed | +5.2% | +16.8% | +2.5% | +7.6% | +7.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 4 | 5 | 5 |
| Debt / EquityFinancial leverage | 1.14x | 0.00x | 1.32x | 0.55x | 1.82x |
| Net DebtTotal debt minus cash | $3.8B | -$61M | $3.9B | $390M | $3.7B |
| Cash & Equiv.Liquid assets | $240M | $62M | $4M | $36M | $27M |
| Total DebtShort + long-term debt | $4.0B | $491,000 | $3.9B | $426M | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | 1.35x | — | 5.98x | 15.42x | 4.41x |
Total Returns (Dividends Reinvested)
KNTK leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KNTK five years ago would be worth $19,312 today (with dividends reinvested), compared to $2,773 for SGRY. Over the past 12 months, KNTK leads with a +28.0% total return vs SGRY's -38.2%. The 3-year compound annual growth rate (CAGR) favors KNTK at 24.7% vs SGRY's -25.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -6.2% | -18.3% | +37.4% | -24.6% | +11.4% |
| 1-Year ReturnPast 12 months | -38.2% | -29.2% | +28.0% | -14.3% | +11.1% |
| 3-Year ReturnCumulative with dividends | -59.2% | -24.8% | +93.9% | -43.7% | +7.4% |
| 5-Year ReturnCumulative with dividends | -72.3% | -18.9% | +93.1% | -43.4% | -11.1% |
| 10-Year ReturnCumulative with dividends | -0.6% | +31.8% | -33.5% | +22.6% | +158.5% |
| CAGR (3Y)Annualised 3-year return | -25.8% | -9.1% | +24.7% | -17.4% | +2.4% |
Risk & Volatility
Evenly matched — AMSF and SEM each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMSF is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than SGRY's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SEM currently trades 96.8% from its 52-week high vs SGRY's 59.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 0.23x | 0.60x | 0.93x | 0.46x |
| 52-Week HighHighest price in past year | $24.18 | $48.54 | $51.11 | $93.50 | $16.99 |
| 52-Week LowLowest price in past year | $11.41 | $29.42 | $31.33 | $58.55 | $11.65 |
| % of 52W HighCurrent price vs 52-week peak | +59.2% | +62.4% | +94.8% | +63.1% | +96.8% |
| RSI (14)Momentum oscillator 0–100 | 63.3 | 34.2 | 51.3 | 46.1 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 212K | 1.2M | 171K | 2.1M |
Analyst Outlook
Evenly matched — KNTK and USPH each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SGRY as "Buy", AMSF as "Buy", KNTK as "Buy", USPH as "Buy", SEM as "Hold". Consensus price targets imply 72.9% upside for USPH (target: $102) vs -1.8% for KNTK (target: $48). For income investors, KNTK offers the higher dividend yield at 16.47% vs SEM's 1.55%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $18.60 | $44.50 | $47.57 | $102.00 | $18.00 |
| # AnalystsCovering analysts | 22 | 6 | 15 | 12 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | +8.4% | +16.5% | +3.1% | +1.5% |
| Dividend StreakConsecutive years of raises | 0 | 0 | 3 | 5 | 0 |
| Dividend / ShareAnnual DPS | — | $2.55 | $7.98 | $1.80 | $0.25 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.1% | +5.3% | +0.6% | +4.9% |
AMSF leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SEM leads in 1 (Valuation Metrics). 2 tied.
SGRY vs AMSF vs KNTK vs USPH vs SEM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SGRY or AMSF or KNTK or USPH or SEM a better buy right now?
For growth investors, Kinetik Holdings Inc.
(KNTK) is the stronger pick with 19. 0% revenue growth year-over-year, versus 2. 6% for AMERISAFE, Inc. (AMSF). AMERISAFE, Inc. (AMSF) offers the better valuation at 12. 3x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Surgery Partners, Inc. (SGRY) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SGRY or AMSF or KNTK or USPH or SEM?
On trailing P/E, AMERISAFE, Inc.
(AMSF) is the cheapest at 12. 3x versus U. S. Physical Therapy, Inc. at 41. 5x. On forward P/E, Select Medical Holdings Corporation is actually cheaper at 13. 1x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SGRY or AMSF or KNTK or USPH or SEM?
Over the past 5 years, Kinetik Holdings Inc.
(KNTK) delivered a total return of +93. 1%, compared to -72. 3% for Surgery Partners, Inc. (SGRY). Over 10 years, the gap is even starker: SEM returned +158. 5% versus KNTK's -33. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SGRY or AMSF or KNTK or USPH or SEM?
By beta (market sensitivity over 5 years), AMERISAFE, Inc.
(AMSF) is the lower-risk stock at 0. 23β versus Surgery Partners, Inc. 's 1. 04β — meaning SGRY is approximately 352% more volatile than AMSF relative to the S&P 500. On balance sheet safety, AMERISAFE, Inc. (AMSF) carries a lower debt/equity ratio of 0% versus 182% for Select Medical Holdings Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — SGRY or AMSF or KNTK or USPH or SEM?
By revenue growth (latest reported year), Kinetik Holdings Inc.
(KNTK) is pulling ahead at 19. 0% versus 2. 6% for AMERISAFE, Inc. (AMSF). On earnings-per-share growth, the picture is similar: Kinetik Holdings Inc. grew EPS 157. 8% year-over-year, compared to -28. 9% for Select Medical Holdings Corporation. Over a 3-year CAGR, KNTK leads at 13. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SGRY or AMSF or KNTK or USPH or SEM?
AMERISAFE, Inc.
(AMSF) is the more profitable company, earning 14. 9% net margin versus -2. 4% for Surgery Partners, Inc. — meaning it keeps 14. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMSF leads at 18. 6% versus 6. 1% for SEM. At the gross margin level — before operating expenses — AMSF leads at 46. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SGRY or AMSF or KNTK or USPH or SEM more undervalued right now?
On forward earnings alone, Select Medical Holdings Corporation (SEM) trades at 13.
1x forward P/E versus 42. 4x for Kinetik Holdings Inc. — 29. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USPH: 72. 9% to $102. 00.
08Which pays a better dividend — SGRY or AMSF or KNTK or USPH or SEM?
In this comparison, KNTK (16.
5% yield), AMSF (8. 4% yield), USPH (3. 1% yield), SEM (1. 5% yield) pay a dividend. SGRY does not pay a meaningful dividend and should not be held primarily for income.
09Is SGRY or AMSF or KNTK or USPH or SEM better for a retirement portfolio?
For long-horizon retirement investors, AMERISAFE, Inc.
(AMSF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), 8. 4% yield). Both have compounded well over 10 years (AMSF: +31. 8%, SGRY: -0. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SGRY and AMSF and KNTK and USPH and SEM?
These companies operate in different sectors (SGRY (Healthcare) and AMSF (Financial Services) and KNTK (Energy) and USPH (Healthcare) and SEM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SGRY is a small-cap quality compounder stock; AMSF is a small-cap deep-value stock; KNTK is a small-cap high-growth stock; USPH is a small-cap high-growth stock; SEM is a small-cap deep-value stock. AMSF, KNTK, USPH, SEM pay a dividend while SGRY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.